Eledon Pharmaceuticals, Inc. (ELDN)
3.42
+0.01
(+0.29%)
USD |
NASDAQ |
Aug 25, 12:23
Eledon Pharmaceuticals EPS Diluted (Quarterly) : -0.2784 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2784 |
| March 31, 2026 | -0.3471 |
| December 31, 2025 | -0.1385 |
| September 30, 2025 | -0.2263 |
| June 30, 2025 | -0.1454 |
| March 31, 2025 | -0.0842 |
| December 31, 2024 | -0.7462 |
| September 30, 2024 | -0.3155 |
| June 30, 2024 | -1.062 |
| March 31, 2024 | -0.788 |
| December 31, 2023 | -3.545 |
| September 30, 2023 | -0.3305 |
| June 30, 2023 | -2.739 |
| March 31, 2023 | -0.754 |
| December 31, 2022 | -4.238 |
| September 30, 2022 | -0.734 |
| June 30, 2022 | -0.6482 |
| March 31, 2022 | -0.6883 |
| December 31, 2021 | -0.6155 |
| September 30, 2021 | -0.6626 |
| June 30, 2021 | -0.4984 |
| March 31, 2021 | -0.573 |
| December 31, 2020 | -0.3894 |
| September 30, 2020 | -5.515 |
| June 30, 2020 | -2.741 |
| Date | Value |
|---|---|
| March 31, 2020 | -8.524 |
| December 31, 2019 | -5.752 |
| September 30, 2019 | -4.014 |
| June 30, 2019 | -6.270 |
| March 31, 2019 | -9.320 |
| December 31, 2018 | -8.738 |
| September 30, 2018 | -6.680 |
| June 30, 2018 | -6.12 |
| March 31, 2018 | -6.48 |
| December 31, 2017 | -5.40 |
| September 30, 2017 | -7.74 |
| June 30, 2017 | -23.76 |
| March 31, 2017 | -95.58 |
| December 31, 2016 | -92.34 |
| September 30, 2016 | -704.70 |
| June 30, 2016 | -364.50 |
| March 31, 2016 | -82.62 |
| December 31, 2015 | -79.38 |
| September 30, 2015 | -85.86 |
| June 30, 2015 | -64.80 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | -45.36 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | -41.55 |
| March 31, 2014 | -34.42 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 4.310 |
| Viking Therapeutics, Inc. | -1.101 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -31.63M |
| Total Expenses (Quarterly) | 31.63M |
| Enterprise Value | 226.57M |
| Earnings Yield | -28.96% |
| Normalized Earnings Yield | -26.78 |